JAZZ
NASDAQ · Pharmaceuticals
Jazz Pharmaceuticals Plc
$243.11
+8.35 (+3.56%)
Financial Highlights (FY 2026)
Revenue
4.49B
Net Income
-374,819,438
Gross Margin
88.2%
Profit Margin
-8.4%
Rev Growth
+5.3%
D/E Ratio
1.24
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 88.2% | 88.2% | 35.9% | 35.9% |
| Operating Margin | -10.1% | -9.1% | 25.1% | 26.2% |
| Profit Margin | -8.4% | -7.9% | 28.9% | 24.4% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 4.49B | 4.27B | 1.73B | 1.70B |
| Gross Profit | 3.96B | 3.76B | 622.43M | 609.30M |
| Operating Income | -452,725,620 | -387,092,017 | 435.37M | 444.25M |
| Net Income | -374,819,438 | -320,480,233 | 500.28M | 414.07M |
| Gross Margin | 88.2% | 88.2% | 35.9% | 35.9% |
| Operating Margin | -10.1% | -9.1% | 25.1% | 26.2% |
| Profit Margin | -8.4% | -7.9% | 28.9% | 24.4% |
| Rev Growth | +5.3% | +5.3% | +7.8% | +14.0% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 4.17B | 4.17B | 3.35B | 3.35B |
| Total Equity | 3.36B | 3.36B | 6.96B | 7.49B |
| D/E Ratio | 1.24 | 1.24 | 0.48 | 0.45 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 236.19M | 213.17M | 730.31M | 605.53M |
| Free Cash Flow | — | — | 376.40M | 328.43M |